Rituximab Current Events | Rituximab News
|
|
|
Sort By:
Page Views | Date |
New treatment strategy offers hope to RA patients who failed all other therapies
Rheumatoid arthritis (RA) patients who failed to respond to initial treatment with rituximab (RTX) (a chimeric monoclonal antibody against the protein CD20) can still be successfully re-treated with a second course of RTX after six months. view more (2009-06-12)
New evidence shows Rituximab halts damage to joints
New data, presented today at the Annual European Congress of Rheumatology show for the first time that a rheumatoid arthritis (RA) treatment, rituximab, is able to significantly inhibit the structural damage to joints caused by RA in patients who have long-standing disease and an inadequate response to one or more TNF (Tumour Necrosis Factor)... view more... (2006-06-23)
Researchers find new way to attack inflammation in Graves' eye disease
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. view more (2009-11-09)
Targeted drug therapy found effective in patients with common form of immune-mediated kidney disease
The drug rituximab causes considerable kidney injury healing in patients with membranous nephropathy, a common form of kidney disease, according to a study appearing in the November 2008 issue of the Clinical Journal of the American Society Nephrology (CJASN). The results suggest that this condition, previously destined to progress to kidney... view more... (2008-08-06)
New treatment approach promising for lymphoma patients in the developing world
Preliminary results suggest that patients with aggressive non-Hodgkin's lymphoma in the developing world might benefit from a modified chemotherapy regimen, researchers say. view more (2008-07-07)
May: Multiple Sclerosis Awareness Month -- latest research is good news
May is Multiple Sclerosis Month and there is no better way of raising awareness for this unpredictable and often debilitating disease then by highlighting the latest research that might offer hope for the 55 to 75, 000 sufferers across Canada. view more (2007-05-03)
Cancer drug hope for people with lupus
A drug used to treat cancer may also benefit people with lupus who have complications of the central nervous system. Rheumatologists at the Annual European Congress of Rheumatology in Vienna, Austria heard today (Thursday 9 June) that rituximab is the first drug in a quarter of a century that is making a real impact, and an alternative to previous... view more... (2005-06-09)
Study shows rituximab effective in treating chronic graft-versus-host disease
A study by Dana-Farber Cancer Institute researchers offers the strongest evidence yet of the effectiveness of a novel therapy for chronic graft-versus-host disease (GVHD), a potentially life-threatening complication of donor bone marrow and stem cell transplants. view more (2006-03-27)
Cancer and arthritis therapy may be promising treatment for diabetes
An antibody used to treat certain cancers and rheumatoid arthritis appears to greatly delay type 1 diabetes in mice, Yale School of Medicine researchers report in the Journal of Clinical Investigation. view more (2007-12-19)
Study shows that maintenance rituximab is useful for advanced indolent lymphoma
A new study has found for the first time that maintenance therapy with the novel antibody, rituximab (MR) following cyclophosphamide, vincristine and prednisone (CVP) therapy improves progression-free survival in patients with stage III-IV indolent lymphoma. view more (2009-03-11)
Study to test drug's potential to preserve insulin production in newly diagnosed Type 1 diabetics
A drug used to treat lymphoma, rheumatoid arthritis and other immune disorders may enable newly-diagnosed type 1 diabetics to save some of their pancreas function and thereby reduce their susceptibility to long-term complications. view more (2006-03-16)
Two targeted therapies likely better than one in patients with aggressive lymphoma
When combined with a cocktail of chemotherapy drugs, two monoclonal antibodies, instead of one, appear to offer superior results in patients with diffuse large B-cell lymphoma, according to Mayo Clinic researchers working with the North Central Cancer Treatment Group (NCCTG). view more (2009-05-15)
Popular cancer drug linked to often fatal brain virus
The 57-year-old lawyer in New York had handily completed the New York Times' Saturday crossword puzzle - the hardest of the week - for years. But one Saturday morning, suddenly he couldn't retrieve the words to fill in the squares. view more (2009-05-19)
Adding epratuzumab to standard therapy
Adding a second monoclonal antibody drug to chemotherapy looks promising for treatment of diffuse large B-cell lymphoma. view more (2008-05-16)
Intense chemotherapy wards off recurrence in half of mantle cell lymphoma patients after seven years
More than half of younger mantle cell lymphoma patients who received an intensive regimen of chemotherapy as frontline treatment remain in remission seven years later, researchers at The University of Texas M. D. Anderson Cancer Center report today at the 50th annual meeting of the American Society of Hematology. view more (2008-12-10)
Experimental MS drug shows promise, offers new window on disease
A drug therapy currently used to treat non-Hodgkin's lymphoma and rheumatoid arthritis had a significant effect in treating the most common form of multiple sclerosis in a small, short-term clinical trial. view more (2008-02-14)
Mayo Clinic Cancer Center collaborating to find new tools to fight leukemia
Mayo Clinic Cancer Center, working in collaboration with Ohio State University Comprehensive Cancer Center, presented evidence Sunday that a novel regimen of three chemotherapy drugs, pentostatin, cyclophosphamide and rituximab, resulted in significant clinical response in patients with previously untreated chronic lymphocytic leukemia (CLL). view more (2006-12-11)
Immune system finding paves way for vaccine use in some leukemia, lymphoma cancers
Researchers at The University of Texas M. D. Anderson Cancer Center and the National Cancer Institute have found that an experimental vaccine can prime the immune system to help fight an aggressive form of lymphoma. view more (2005-08-23)
New therapy prevents dangerous side effect for lymphoma patients
Patients respond well to a new three-drug combination for indolent B cell lymphoma that also spares them prolonged, potentially lethal, suppression of blood production in the bone marrow, researchers at The University of Texas M. D. Anderson Cancer Center report today at the 50th annual meeting of the American Society of Hematology. view more (2008-12-10)
FLT PET Assesses Treatment Response on Tumor Growth—Not Size—With Non-Hodgkin's Lymphoma
Positron emission tomography (PET)—with the radiolabeled thymidine analog [18F]Fluorothymidine (FLT)—is "a promising, sensitive tool" for assessing drug effects on tumor growth in patients with diffuse large B-cell lymphoma. view more (2006-06-07)
|
|
|
|
Sort By:
Page Views | Date |
|
